PDCD1 and gastric cancer: Related studies have demonstrated that in advanced GC patients receiving PD‐1 inhibitor therapy, pATB was associated with reduced gut microbial diversity, suppression of Lactobacillus gasseri, and dysregulation of circulating exhausted CD8+ T cells after treatment, which subsequently resulted in significantly decreased PFS and OS.